Phase 2 Trial of Selinexor Shows Durable Responses in DLBCL
Michael Schuster, MD, discusses the efficacy of treatment with selinexor in patients with diffuse large B-cell lymphoma in the SADAL study.
Michael Schuster, MD, director of the Bone Marrow Transplant Program at Stony Brook Cancer Center, discusses the efficacy of treatment with selinexor (Xpovio) in patients with diffuse large B-cell lymphoma (DLBCL) in the SADAL study (NCT02227251).
Schuster says that the good news is, for this heavily pre-treated population, almost a quarter of those patients had a response to selinexor. Some patients also went into complete remission (CR). These CRs went over 2 years without any evidence of progression of the disease. There were 2 patients in their 70s with heavily pretreated disease who both went into CR and are now approaching 2 years without any evidence of progression.
The most interesting thing is that this drug has a novel mechanism of action, according to Schuster. That is something that physicians can give to patients with DLBCL who have already been through chemotherapy regimens. He hopes that they can respond to this drug with a novel mechanism of action, and if they do respond that the response has a significant duration. Also, because selinexor is an oral agent, it is something that patients can take at home rather than having to come into the hospital for intravenous chemotherapy.
Peers Discuss Role of Pola-R-CHP vs R-CHOP in Newly Diagnosed DLBCL
April 19th 2024During a Case-Based Roundtable® event, Haifaa Abdulhaq, MD discussed with participants whether the POLARIX trial influences their choice to use the pola-R-CHP as opposed to R-CHOP regimen for patients with newly diagnosed diffuse large B-cell lymphoma.
Read More
Challenges for Non–CAR T-Cell Treatment of Early Relapsed DLBCL
April 18th 2024During a Case-Based Roundtable® event, Elizabeth A. Brém, MD, discussed treatment approaches for a patient with early relapsed or primary refractory diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
